Baldur-Felskov Birgitte, Dehlendorff Christian, Junge Jette, Munk Christian, Kjaer Susanne K
Virus, Lifestyle and Genes, Danish Cancer Society Research Center, 2100, Copenhagen, Denmark.
Cancer Causes Control. 2014 Jul;25(7):915-22. doi: 10.1007/s10552-014-0392-4. Epub 2014 May 6.
Approximately 70% of cervical cancers and about 50% of high-grade cervical precursor lesions are caused by human papillomavirus (HPV) types 16 and 18. Denmark introduced the quadrivalent HPV vaccine into the vaccination program for 12-year-old girls in 2009 supplemented by a first catch-up program for 13-15-year-old girls in 2008, and a second program for women up to the age of 27 years in 2012; all with high vaccination coverage. The aim of this study was to evaluate the effectiveness of the vaccine by comparing the incidence trends of cervical lesions before and after its introduction.
Incident cases of cervical lesions were identified from the nationwide Pathology Data Bank. Age-specific incidence rates were estimated for six age groups, and Poisson regression was used to calculate estimated annual percentage change (EAPC).
The incidence of atypia or worse (atypia+) and cervical intraepithelial neoplasia grade 2 or worse (CIN2+) increased in all age groups in 2000-2010. After introduction of the quadrivalent HPV vaccine into the vaccination program, the incidence of atypia+ decreased significantly in women younger than 18 years (EAPC -33.4%; 95% CI -49.6; -12.0) and in 18-20-year-old women (EAPC -12.6%; 95% CI -19.3; -5.3). The incidence of CIN2+ also decreased significantly in 18-20-year-old women (EAPC -14.8%; 95% CI -21.6; -7.5) in 2010-2013, but no significant decrease was seen in older age groups.
The incidence of cervical lesions decreased significantly in age groups with high HPV vaccine coverage, indicating an early effect of HPV vaccination.
约70%的宫颈癌和约50%的高级别宫颈前驱病变由16型和18型人乳头瘤病毒(HPV)引起。丹麦于2009年将四价HPV疫苗引入针对12岁女孩的疫苗接种计划,并于2008年为13 - 15岁女孩补充了首个补种计划,2012年为27岁及以下女性开展了第二个计划;所有计划的疫苗接种覆盖率都很高。本研究的目的是通过比较疫苗引入前后宫颈病变的发病率趋势来评估疫苗的有效性。
从全国病理学数据库中识别宫颈病变的发病病例。估计了六个年龄组的年龄特异性发病率,并使用泊松回归计算估计的年百分比变化(EAPC)。
2000 - 2010年所有年龄组中不典型增生或更严重病变(不典型增生+)和宫颈上皮内瘤变2级或更严重病变(CIN2+)的发病率均有所上升。在将四价HPV疫苗引入疫苗接种计划后,18岁以下女性(EAPC - 33.4%;95%CI - 49.6;- 12.0)和18 - 20岁女性(EAPC - 12.6%;95%CI - 19.3;- 5.3)中不典型增生+的发病率显著下降。2010 - 2013年,18 - 20岁女性中CIN2+的发病率也显著下降(EAPC - 14.8%;95%CI - 21.6;- 7.5),但在年龄较大的组中未观察到显著下降。
HPV疫苗覆盖率高的年龄组中宫颈病变的发病率显著下降,表明HPV疫苗接种具有早期效果。